InspireMD, Inc. (NSPR) Reports Q3 Loss, Tops Revenue Estimates

Company Performance - InspireMD, Inc. reported a quarterly loss of $0.16 per share, better than the Zacks Consensus Estimate of a loss of$0.20, and compared to a loss of $0.15 per share a year ago, representing an earnings surprise of 20$1.81 million for the quarter ended September 2024, surpassing the Zacks Consensus Estimate by 4.02%, and compared to year-ago revenues of $1.56 million [2] - Over the last four quarters, InspireMD has surpassed consensus EPS estimates two times and topped consensus revenue estimates three times [2] Stock Outlook - InspireMD shares have lost about 12.6$0.20 on $1.83 million in revenues, and for the current fiscal year, it is -$0.82 on $6.83 million in revenues [7] - The estimate revisions trend for InspireMD is mixed, resulting in a Zacks Rank 3 (Hold) for the stock, indicating expected performance in line with the market in the near future [6] Industry Context - The Medical - Instruments industry, to which InspireMD belongs, is currently in the top 27% of over 250 Zacks industries, suggesting a favorable outlook [8] - Empirical research indicates a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can impact stock performance [5]